Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 617
Filter
Add more filters

Complementary Medicines
Publication year range
2.
Int Arch Allergy Immunol ; 185(6): 545-589, 2024.
Article in English | MEDLINE | ID: mdl-38442688

ABSTRACT

BACKGROUND: This scoping review aims to critically assess gaps in the current literature on atopic dermatitis (AD) by evaluating the overall effectiveness of dietary interventions. Through a comprehensive analysis that follows the Preferred Reporting Item for Systematic Review and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines, we conducted a thorough search on the Web of Science database in May 2023 using specific search strategies to identify all relevant studies on the research topic. SUMMARY: A total of 104 full-text articles were included for review. Our synthesis identified seven notable categories of dietary interventions for AD, showcasing the diversity of interventions utilized. This includes vitamin supplementation, probiotic and prebiotic supplementation, dietary fat, biological compounds, foods from natural sources, major nutrients, and diet-related approaches. Further analyses stratified by targeted populations revealed a predominant focus on pediatrics, particularly in probiotic supplementation, and on adults, with an emphasis on vitamin D and E supplementation. KEY MESSAGES: Despite most dietary interventions demonstrating overall effectiveness in improving AD severity and its subjective symptoms, several significant gaps were identified. There was a scarcity of studies on adults and whole-diet interventions, a prevalence of short-term interventions, heterogeneity in study outcomes, designs, and population, occasional disparity between statistical significance and clinical relevance, and a lack of a comprehensive multidisciplinary approach. Nonetheless, these findings offer valuable insights for future AD research, guiding additional evidence-driven dietary interventions and informing healthcare professionals, researchers, and individuals, advancing both understanding and management of AD.


Subject(s)
Dermatitis, Atopic , Dietary Supplements , Probiotics , Dermatitis, Atopic/diet therapy , Dermatitis, Atopic/therapy , Humans , Probiotics/therapeutic use , Probiotics/administration & dosage , Diet , Prebiotics/administration & dosage
3.
Int J Biometeorol ; 68(6): 1005-1013, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38530467

ABSTRACT

Balneotherapy includes practices and methods using medically and legally recognized mineral-medicinal waters, muds and natural gases from natural springs for therapeutic purposes. One of the most widely used method in balneotherapy is bathing with thermal mineral water. In the course of the years, scientific community has produced an increasing number of evidences that this practice is an effective method for treating signs and symptoms of several pathologies such as rheumatic, cardiovascular and dermatological diseases. This systematic review is aimed at evaluating the effect of balneotherapy with thermal water baths as a treatment to manage signs and symptoms of patients affected by all types of dermatological diseases. The systematic review was conducted according to the PRISMA Statement, and its protocol was registered on PROSPERO platform (CRD42022295913). The research was performed on the databases Pubmed, Scopus, Web of Science and Cochrane. We included clinical trials evaluating the effects of balneotherapy using thermal mineral water baths for managing dermatological diseases in humans, published in English and Italian language. Eight studies were included, seven of them enrolled adults affected by psoriasis and one studied atopic dermatitis patients. The common result of all the articles included was a clear improvement of signs and symptoms of psoriasis and eczematous diseases after use of thermal mineral water baths. These effects seem to be strictly related to physical and chemical properties of thermal water used for balneotherapy. However, studies in this field are still limited to support robust evidence of the effectiveness of balneotherapy using thermal mineral water baths and often their quality is low. Thus, new clinical studies need to be carried out, using more correct methods for conducting the studies and for processing statistical data.


Subject(s)
Balneology , Baths , Mineral Waters , Skin Diseases , Humans , Mineral Waters/analysis , Mineral Waters/therapeutic use , Skin Diseases/therapy , Dermatitis, Atopic/therapy , Psoriasis/therapy
4.
J Dermatolog Treat ; 35(1): 2315145, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38387879

ABSTRACT

BACKGROUND: Understanding the patient journey is important to optimize care for patients with atopic dermatitis (AD) and overcome challenges in diagnosis and management. OBJECTIVE: To explore patient and caregiver perspectives regarding their experience with AD. METHODS: Patients and caregivers of patients with AD completed a pre-meeting survey and were invited to join an advisory board meeting in their country (China, Hong Kong, Ireland, Japan and Lebanon) to discuss the survey results. Data were analyzed descriptively. RESULTS: The survey included 31 participants (patients and caregivers) from Hong Kong (n = 7), China (n = 7), Ireland (n = 6), Japan (n = 6) and Lebanon (n = 5). The most challenging factors in the AD journey were management of symptoms before a confirmed diagnosis (68%), sudden recurrence of flares or worsening of symptoms (68%) and lifestyle changes (52%). In terms of overall AD management, 35% of participants indicated that AD was managed well, 23% had a clear treatment plan and 19% were generally satisfied with disease management. A collaborative relationship with healthcare professionals was favored. CONCLUSION: A holistic assessment of AD includes understanding patient and caregiver preferences, needs, experiences and disease perceptions. Addressing the identified gaps may improve the management of AD.


Subject(s)
Caregivers , Dermatitis, Atopic , Humans , Dermatitis, Atopic/therapy , Life Style , Surveys and Questionnaires , Health Personnel
5.
Photodermatol Photoimmunol Photomed ; 40(1): e12948, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38288769

ABSTRACT

BACKGROUND: Phototherapy is a mainstay to treat itchy conditions. However, only little is known about differences in the antipruritic effect of phototherapy amongst different skin conditions, phototypes and genders. METHODS: In this prospective, single-center study, we analyzed the effect of phototherapy on itch intensity and itch-related quality of life amongst these subgroups after a treatment duration of 4 weeks, while on-demand treatment with topical corticosteroids, topical calcineurin inhibitors and/or antihistamines was allowed. RESULTS: Of 102 patients (age 53.0 ± 18.7, 56 females [54.9%]), 72 (78.3%) reported a significant reduction of itch intensity by Δ -2.76 on a 0-10 Numerical Rating Scale (NRS), p = <.001, 95% CI [2.2; 3.3] paralleled by a significant improvement of itch-related quality of life as measured by the German version of the ItchyQoL by Δ 7.3, p = <.001, 95% CI [4.4; 11.6]. The best improvement of itch intensity and itch-related QoL was reported by patients with pruritus on non-diseased skin (ΔNRS -3.5; Δ 9.7 Ger-ItchyQoL points), followed by patients with atopic dermatitis and psoriasis. We found no statistical differences in the response to phototherapy amongst Fitzpatrick phototypes I-VI. Women had higher itch intensities at baseline but itch-related quality of life impairment at baseline and phototherapy treatment response did not significantly differ between genders. CONCLUSION: Phototherapy appears to induce a meaningful itch reduction in various itchy skin conditions, all phototypes and both genders within 4 weeks that directly translates into improvement of itch-related quality of life.


Subject(s)
Dermatitis, Atopic , Quality of Life , Humans , Female , Male , Prospective Studies , Pruritus/etiology , Pruritus/therapy , Phototherapy , Dermatitis, Atopic/complications , Dermatitis, Atopic/therapy
6.
J Allergy Clin Immunol Pract ; 12(4): 824-837, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38278324

ABSTRACT

Treatable traits is a personalized medicine approach to the management of airway disease. Assessing traits within the 3 domains of pulmonary, extrapulmonary, and behavioral/lifestyle/risk factor traits, and applying targeted treatments to effectively manage these traits, enables a holistic and personalized approach to care. Asthma is a heterogeneous and complex airway disease that is frequently complicated by several extrapulmonary traits that impact asthma outcomes and predict future outcomes. We propose that the identification of extrapulmonary and behavioral risk factor traits and the implementation of targeted therapy will lead to improved management of people with asthma. Furthermore, many extrapulmonary traits present as "connected comorbidities"; that is, they coexist with asthma, have an impact on asthma, and effective treatment improves both asthma and the comorbidity or the comorbidities may share a similar mechanism. In this review, we explore this concept and look at atopic dermatitis, chronic rhinosinusitis with nasal polyps, gastroesophageal reflux disease, anxiety, and depression as treatable traits of asthma and how these can be managed using this approach.


Subject(s)
Asthma , Dermatitis, Atopic , Gastroesophageal Reflux , Nasal Polyps , Humans , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/therapy , Depression/epidemiology , Depression/therapy , Asthma/epidemiology , Asthma/therapy , Gastroesophageal Reflux/epidemiology , Gastroesophageal Reflux/therapy , Chronic Disease , Anxiety
7.
Am J Pharm Educ ; 88(2): 100651, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38218340

ABSTRACT

OBJECTIVE: To explore the impact of lived experiences of pharmacy students with atopic dermatitis (AD) on perceptions of learning in pharmacy curriculum. METHODS: An exploratory qualitative study was conducted with pharmacy students in the United Kingdom to understand how their lived experiences affect their perception of AD in pharmacy curriculum. Semistructured interviews were conducted, and a thematic analysis method was followed. Firstly, codes were created, and then relevant codes were combined to identify themes. RESULTS: Thirteen pharmacy students were interviewed. Study findings showed pharmacy students support teaching with a holistic approach to management and patient-centered care in AD in pharmacy curriculum. Although students had empathy and moral support for patients, they also described a need for teaching on the mental health effects of AD in pharmacy education. CONCLUSION: This brief report explores the role of lived experience of pharmacy students in considering the provision of holistic, patient-centered care in AD teaching in pharmacy education. Participants also suggest the need within the pharmacy curriculum for training to provide mental health advice to patients with AD.


Subject(s)
Dermatitis, Atopic , Education, Pharmacy , Students, Pharmacy , Humans , Students, Pharmacy/psychology , Dermatitis, Atopic/therapy , Education, Pharmacy/methods , Curriculum , Learning
8.
J Dtsch Dermatol Ges ; 22(1): 137-153, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38171719

ABSTRACT

This S3 guideline was created based on the European S3 guideline, with special consideration of the medical conditions in the German-speaking region and incorporating additions from the previous German-language version. The interdisciplinary guideline commission consisted of representatives from the German Dermatological Society, the Professional Association of German Dermatologists, the Austrian Society of Dermatology and Venereology, the Swiss Society of Dermatology and Venereology, the German Society for Allergology and Clinical Immunology, the German Society for Pediatric and Adolescent Medicine, the Professional Association of Pediatricians and Adolescent Medicine, the Society for Pediatric Allergology and Environmental Medicine, the German Society for Pediatric Rehabilitation and Prevention, the German Society for Psychosomatic Medicine and Medical Psychotherapy, the German Network for Health Services Research, the German Eczema Association and the German Allergy and Asthma Association. This first part of the guideline focuses on the definition and diagnostic aspects of atopic dermatitis (AD), addressing topical therapy as well as non-pharmacological treatment approaches such as UV therapy, psychoeducational therapy, dietary interventions for AD, allergen immunotherapy for AD, and complementary medicine. This part of the guideline also covers specific aspects of AD in children and adolescents, during pregnancy and lactation, and in the context of family planning. Additionally, it addresses occupational aspects of AD and highlights the perspective of the patients. The second part of the guideline, published separately, addresses the systemic therapy of AD.


Subject(s)
Asthma , Dermatitis, Atopic , Adolescent , Female , Pregnancy , Humans , Child , Dermatitis, Atopic/therapy , Dermatitis, Atopic/drug therapy
9.
J Eur Acad Dermatol Venereol ; 38(3): 521-529, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38011002

ABSTRACT

BACKGROUND: Phototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost-effectiveness and short- and long-term safety with real-life usage is weak. OBJECTIVES: We established a taskforce to examine how phototherapy is currently being used as a treatment for AD across the United Kingdom and Europe to inform our understanding and guide future research into management of patients with AD using UV-based phototherapies. METHODS: An anonymous electronic multiple-response survey exploring phototherapy prescribing practices and experience of phototherapy modalities was developed by the study authors and sent to members of phototherapy networks from the United Kingdom and Europe. Responses were received between February and July 2021. RESULTS: About 144 respondents from 27 European countries completed the survey. NBUVB was the most widely used [n = 138 (96%)]. Home-based NBUVB was available in 8/27 countries (25/144 respondents, 17%). Oral psoralen-UVA (PUVA) was more widely available than bath PUVA (n = 106, 74% vs. n = 60, 42%) and used mainly in adult patients. 49/144 (34%) of respondents had access to UVA1. Phototherapy would be considered instead of systemic treatment in 96% of adults and 82% of children for NBUVB, versus 40% of adults and 3% of children for PUVA. Starting doses, standard dosing increments, length of treatment courses, lifetime limits for treatments and thresholds for performing annual skin assessments varied between responders. CONCLUSIONS: NBUVB was the most widely used phototherapy for AD in adult and paediatric patients, while PUVA and UVA1 were less used. Prescribing practices varied considerably, highlighting the lack of consensus practice in many different aspects of phototherapy for the treatment of AD in children and adults. This indicates that further studies are required to determine optimal phototherapeutic regimens for AD and informs our understanding of parameters that should be included in future high-quality randomized controlled trials (RCT) of phototherapy.


Subject(s)
Dermatitis, Atopic , Ultraviolet Therapy , Adult , Humans , Child , Dermatitis, Atopic/therapy , Phototherapy , Europe , United Kingdom
10.
Pediatr Dermatol ; 41(1): 66-69, 2024.
Article in English | MEDLINE | ID: mdl-38018915

ABSTRACT

Phototherapy is broadly utilized for treatment of inflammatory skin conditions affecting pediatric patients. However, there are no specific guidelines or recommendations for implementing phototherapy in pediatric populations leading to variability in treatment procedures. Here, we present findings from a cross-sectional, survey-based study investigating the implementation of phototherapy in pediatric patients across the United States. A total of 39 sites from 19 different states identified via the National Psoriasis Foundation (NPF) Health Care Provider Directory responded. Common practices included a signed informed consent prior to performing phototherapy (86.4%, n = 32), no minimum age requirement for pediatric patients (91.8%, n = 34), the use of Fitzpatrick skin type to determine dosing protocol (100%, n = 37), and allowing parents to accompany their children into the lightbox (65%, n = 20). Our results provide insights into current common practices and themes for further study.


Subject(s)
Dermatitis, Atopic , Psoriasis , Ultraviolet Therapy , Humans , Child , United States , Cross-Sectional Studies , Ultraviolet Therapy/methods , Phototherapy , Psoriasis/radiotherapy , Psoriasis/etiology , Dermatitis, Atopic/therapy
11.
São Paulo; s.n; 2024. 30 p.
Thesis in Portuguese | MTYCI, HomeoIndex Homeopathy | ID: biblio-1555236

ABSTRACT

Este trabalho apresenta um levantamento bibliográfico sobre a Dermatite Atópica, uma doença inflamatória crônica pruriginosa da pele cuja prevalência vem aumentando continuamente, com importante impacto na qualidade de vida dos pacientes afetados. Serão discutidos sua fisiopatologia, quadro clínico, diagnóstico e tratamentos convencionais e proposta, como possibilidade terapêutica, a Homeopatia, modelo terapêutico fundamentado pelo médico alemão Samuel Hahnemann, uma forma de cuidado voltada ao indivíduo e não à doença. As bases de dados utilizadas foram LILACS, PUBMED, Scielo e livros de Homeopatia.


This work presents a bibliographical survey on Atopic Dermatitis, a chronic itchy inflammatory skin disease whose prevalence is continually increasing, with an important impact on the quality of life of affected patients. Its pathophysiology, clinical picture, diagnosis and conventional treatments will be discussed and Homeopathy, a therapeutic model founded by the German doctor Samuel Hahnemann, will be proposed as a therapeutic possibility, a form of care aimed at the individual and not the disease. The databases used were LILACS, PUBMED, Scielo and Homeopathy books.


Subject(s)
Humans , Homeopathic Remedy , Homeopathic Therapeutics , Dermatitis, Atopic/therapy , Arsenicum Iodatum , Aurum Metallicum , Graphites Naturalis , Natrium Sulphuricum , Sulphur
12.
Curr Opin Pediatr ; 35(6): 686-691, 2023 12 01.
Article in English | MEDLINE | ID: mdl-37779485

ABSTRACT

PURPOSE OF REVIEW: Atopic dermatitis is a chronic, systemic disease with primary cutaneous clinical manifestations and is commonly attributed to an exaggerated Th2 inflammatory response. Recent research regarding risk factors, prevention, clinical features, and management of atopic dermatitis will be reviewed. RECENT FINDINGS: In the last decade, advances have been made in identifying the factors that either confer increased risk for or protection from atopic dermatitis and associated atopy. Progress has also been made in the clinical management of this disease. Promising biomarkers and therapeutically informative characteristics of this disease have been identified in young children with and without the presence of eczema, but much has yet to be elucidated. Progress has also been made in clarifying the advantages and disadvantages of respective medical managements, including but not limited to topical corticosteroids, topical calcineurin inhibitors, phototherapy, systemic immunosuppressants, and targeted immunotherapy. Given that medical management may show variable efficacy in a child, an optimized skin care regimen is of utmost importance as well. SUMMARY: Atopic dermatitis is a challenging, chronic systemic disease that incurs significant morbidity in affected children. Although management options have been somewhat disappointing in years past, promising results have been observed in recent advances in targeted immunotherapy.


Subject(s)
Dermatitis, Atopic , Dermatologic Agents , Child , Humans , Child, Preschool , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/therapy , Calcineurin Inhibitors/therapeutic use , Immunosuppressive Agents/therapeutic use , Phototherapy , Dermatologic Agents/therapeutic use
13.
Nutrients ; 15(17)2023 Sep 04.
Article in English | MEDLINE | ID: mdl-37686888

ABSTRACT

Recently, the prevalence of atopic dermatitis has increased drastically, especially in urban populations. This multifactorial skin disease is caused by complex interactions between various factors including genetics, environment, lifestyle, and diet. In eczema, apart from using an elimination diet, the adequate content of fatty acids from foods (saturated, monounsaturated, and polyunsaturated fatty acids) plays an important role as an immunomodulatory agent. Different aspects regarding atopic dermatitis include connections between lipid metabolism in atopic dermatitis, with the importance of the MUFA levels, as well as of the omega-6/omega-3 balance that affects the formation of long-chain (C20 eicosanoic and C22 docosaenoic) fatty acids and bioactive lipids from them (such as prostaglandins). Impair/repair of the functioning of epidermal barrier is influenced by these fatty acid levels. The purpose of this review is to drive attention to membrane fatty acid composition and its involvement as the target of fatty acid supplementation. The membrane-targeted strategy indicates the future direction for dermatological research regarding the use of nutritional synergies, in particular using red blood cell fatty acid profiles as a tool for checking the effects of supplementations to reach the target and influence the inflammatory/anti-inflammatory balance of lipid mediators. This knowledge gives the opportunity to develop personalized strategies to create a healthy balance by nutrition with an anti-inflammatory outcome in skin disorders.


Subject(s)
Dermatitis, Atopic , Fatty Acids, Omega-3 , Humans , Fatty Acids , Dermatitis, Atopic/therapy , Nutritional Status , Prostaglandins , Food
14.
Adv Pediatr ; 70(1): 157-170, 2023 08.
Article in English | MEDLINE | ID: mdl-37422293

ABSTRACT

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with a lifetime prevalence of up to 20% which can occur at any age but is most common among children. There is a significant burden of pediatric AD in the primary care setting; thus, the ability to recognize and manage AD is of utmost importance to pediatricians. Treatment of AD requires a multifaceted approach based on a patient's severity including behavioral modifications, topical and systemic pharmacologic therapies, and phototherapy.


Subject(s)
Dermatitis, Atopic , Humans , Child , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/therapy , Phototherapy , Behavior Therapy
15.
PLoS One ; 18(6): e0286449, 2023.
Article in English | MEDLINE | ID: mdl-37363912

ABSTRACT

This cross-sectional, retrospective, observational study aimed to analyze the distribution and healthcare usage patterns of patients with atopic dermatitis using the 2010-2018 Health Insurance Review and Assessment Service data. Patients diagnosed with atopic dermatitis in Korea between January 2010 and December 2018 and registered in the Health Insurance Review and Assessment national database were identified, and 270,008 patients who used healthcare services at least once during this period were evaluated to ascertain the healthcare usage patterns and treatment methods for atopic dermatitis. The number of patients with atopic dermatitis plateaued during the study period, while the number of claims and total expenses increased by a small margin. Atopic dermatitis prevalence was the highest among patients aged <5 years (31.4%), followed by those aged 5-14 years (23.53%) and 15-24 years (15.33%). However, the prevalence in these age groups showed a decreasing trend over time. The most used Western medicine treatments were injections and oral medications involving topical corticosteroids, antihistamine agents, and oral steroids, while it was acupuncture therapy in Korean medicine. The frequency of the most frequently prescribed medication, topical corticosteroid, showed a decreasing trend over time. The findings in this study will inform healthcare policy makers and clinicians across different countries on the usage trends of Western medicine and Korean medicine treatment.


Subject(s)
Dermatitis, Atopic , Dermatologic Agents , Humans , Dermatitis, Atopic/therapy , Dermatitis, Atopic/drug therapy , Retrospective Studies , Cross-Sectional Studies , Delivery of Health Care , Insurance, Health , Glucocorticoids/therapeutic use , Dermatologic Agents/therapeutic use , Patient Acceptance of Health Care
16.
Prim Care ; 50(2): 191-203, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37105601

ABSTRACT

Atopic dermatitis (AD) is a common, chronic relapsing, and remitting inflammatory skin disease that is characterized by erythematous, scaly, and pruritic lesions often located over the flexural surfaces. Treatment goals of AD include the reduction of itching and burning, as well as the reduction of skin changes. Treatment of AD includes emollients and skin care, topical therapies including topical corticosteroids and steroid-sparing therapies, systemic therapies, and phototherapy.


Subject(s)
Dermatitis, Atopic , Humans , Dermatitis, Atopic/therapy , Dermatitis, Atopic/drug therapy , Skin , Emollients/therapeutic use , Glucocorticoids/therapeutic use , Phototherapy
17.
J Microbiol Biotechnol ; 33(6): 823-830, 2023 Jun 28.
Article in English | MEDLINE | ID: mdl-36908272

ABSTRACT

Lactococcus lactis is a lactic acid bacterium and used in the dairy food industry. The ameliorating effects of Lactobacillus species on atopic dermatitis (AD) have been extensively studied, but the specific effect of L. lactis strains has not yet been investigated. In this study, the efficacy of L. lactis LB 1022, isolated from natural cheese, was evaluated using RAW 264.7, HMC-1 and HaCaT cell lines and an ovalbumin-sensitized AD mouse model. L. lactis LB 1022 exhibited nitric oxide suppression and anti-allergy and anti-inflammatory activity in vitro. Oral administration of L. lactis LB 1022 to AD mice significantly reduced the levels of IgE, mast cells, and eosinophils, and a range of T cell-mediated T helper Th1, Th2, and Th17-type cytokines under interleukin (IL)-10, transforming growth factor-ß (TGF-ß), thymus and activation-regulated chemokine (TARC), and thymic stromal lymphopoietin (TSLP). In addition, L. lactis LB 1022 treatment increased the concentration of short-chain fatty acids. Overall, L. lactis LB 1022 significantly modulated AD-like symptoms by altering metabolites and the immune response, illustrating its potential as candidate for use in functional food supplements to alleviate AD.


Subject(s)
Dermatitis, Atopic , Immunomodulating Agents , Lactococcus lactis , Animals , Mice , Dermatitis, Atopic/immunology , Dermatitis, Atopic/therapy , RAW 264.7 Cells , Humans , HaCaT Cells , Anti-Inflammatory Agents , Cytokines/blood , Fatty Acids, Volatile/metabolism , Female , Mice, Inbred BALB C , Immunoglobulin E/blood , Nitric Oxide/metabolism , Anti-Allergic Agents , Eosinophils , Mast Cells
18.
Gac Med Mex ; 158(Suplement 2): 1-116, 2023 Jan 20.
Article in Spanish | MEDLINE | ID: mdl-36763412

ABSTRACT

With the advancement of knowledge in relation to the physiopathogenesis of atopic dermatitis (AD), several new therapeutic forms have been developed. There are also new guidelines for self-care. On the other hand, there is still an underdiagnosis of AD in Mexico. Thus, the need was seen to develop a national guide, with a broad base among the different medical groups that care for patients with AD. The Atopic Dermatitis Guidelines for Mexico (GUIDAMEX) was developed with the ADAPTE methodology, with the endorsement and participation of ten national medical societies, from physicians in Primary Healthcare to allergists and dermatologists. Throughout the manuscript, key clinical questions are answered that lead to recommendations and suggestions for the diagnosis of AD (including differential diagnosis with immunodeficiency syndromes), the recognition of comorbidities and complications, non-pharmacological treatment including therapeutic education, treatment of flares and maintenance therapy. The latter encompasses general measures to avoid triggering factors, first-line treatment focussed on repair of the skin barrier, second-line treatment (topical proactive therapy), and third-line phototherapy or systemic treatment, including dupilumab and JAK inhibitors.


Con el avance de los conocimientos en relación con la fisiopatogenia de la dermatitis atópica (DA) se han desarrollado varias formas terapéuticas nuevas. Asimismo, existen nuevos lineamientos para el autocuidado. Por otro lado, aún existe un subdiagnóstico de la DA en México. Así, se vio la necesidad de desarrollar una guía nacional, con base amplia entre las diferentes agrupaciones médicos que atienden pacientes con DA. Se desarrolló la Guía de DA para México (GUIDAMEX) con la metodología ADAPTE, con el aval y la participación de diez sociedades médicas nacionales, desde médicos del primer contacto hasta alergólogos y dermatólogos. A lo largo del escrito se contestan preguntas clínicas clave que llevan a recomendaciones y sugerencias para el diagnóstico de la DA (incluyendo diagnóstico diferencial con síndromes de inmunodeficiencia), el reconocer de las comorbilidades y complicaciones, las medidas generales (tratamiento no farmacológico) incluyendo la educación terapéutica, el tratamiento de los brotes y el tratamiento de mantenimiento. Este último abarca las medidas generales de evitar agravantes, el tratamiento de primera línea reparador de la barrera cutánea, de segunda línea (manejo proactivo tópico), hasta la fototerapia y el tratamiento sistémico de la tercera línea, incluyendo dupilumab y los inhibidores de la cinasa de Jano.


Subject(s)
Dermatitis, Atopic , Humans , Dermatitis, Atopic/therapy , Dermatitis, Atopic/drug therapy , Mexico , Comorbidity , Diagnosis, Differential , Phototherapy/methods
19.
Asian Pac J Allergy Immunol ; 41(1): 30-36, 2023 03.
Article in English | MEDLINE | ID: mdl-32247308

ABSTRACT

BACKGROUND: Few studies have examined the effect of atopic dermatitis (AD) on the resolution of food allergies in Asia, and the predictors of egg allergy resolution are not yet well defined. OBJECTIVE: We evaluated whether AD severity could predict the resolution of egg allergy. METHODS: This retrospective cohort study included infants under 24 months of age diagnosed with IgE-mediated egg white allergy. We included subjects who completed a 60-month follow-up. Open oral food challenges (OFCs) and serologic tests were performed at the time of initial diagnosis and at 36 ± 3 and 60 ± 3 months. RESULTS: We analyzed 68 patients (39 boys and 29 girls). OFCs were performed in 88.2% of the patients. The egg allergy remission rates were 23.5% and 47.1% by 3 and by 5 years of age, respectively. Persistent egg allergy was significantly associated with moderate to severe AD and house dust mite sensitization. Kaplan-Meier curve analysis revealed that patients with moderate to severe AD had higher persistent egg allergy rates than patients with no and mild AD (p = 0.012). Multivariable analysis identified moderate to severe AD as strongly associated with persistent egg allergy (p = 0.001). CONCLUSIONS: In this study, 47.1% of infants had resolved egg white allergies at 60 months. Moderate to severe AD may be a practical and important prognostic factor for persistent egg allergy in clinical settings.


Subject(s)
Dermatitis, Atopic , Egg Hypersensitivity , Male , Infant , Female , Humans , Egg Hypersensitivity/therapy , Egg Hypersensitivity/diagnosis , Allergoids , Retrospective Studies , Immunoglobulin E , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/therapy , Dermatitis, Atopic/complications , Immunotherapy , Allergens , Pollen , Poaceae
20.
Int J Dermatol ; 62(2): 177-189, 2023 Feb.
Article in English | MEDLINE | ID: mdl-35347724

ABSTRACT

BACKGROUND: Atopic dermatitis (AD) and psoriasis are chronic inflammatory diseases that have significant skin complications. OBJECTIVE: The purpose of this systematic study was to evaluate the evidence obtained from human studies on the effects of hydrotherapy, spa therapy, and balneotherapy in psoriasis and atopic dermatitis. METHODS: The present systematic review was conducted according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statements. Also, for this study databases such as Embase, PubMed, Scopus ProQuest, and sciences direct database were searched from the beginning to April 2021. RESULTS: All human studies that examined the effect of balneotherapy, spa therapy, and hydrotherapy on psoriasis and atopic dermatitis were published in the form of a full article in English. In the end, only 22 of the 424 articles met the criteria for analysis. Most studies have shown that balneotherapy, spa therapy, and hydrotherapy may reduce the effects of the disease by reducing inflammation and improving living conditions. In addition, the results of the Downs and Black score show that seven studies received very good scores, three studies received good scores, nine studies received fair scores, and three studies received poor scores. CONCLUSIONS: The results of studies also showed that hydrotherapy leads to an improvement in the PASI score index. Nevertheless, more clinical trials are needed to determine the mechanism of action of hydrotherapy on these diseases.


Subject(s)
Balneology , Dermatitis, Atopic , Hydrotherapy , Psoriasis , Humans , Balneology/methods , Chronic Disease , Dermatitis, Atopic/therapy , Hydrotherapy/methods , Psoriasis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL